Latanoprost (xalatan ) et effet systéntique respiratoire ? A propos d'un cas

Therapie

Volumn 54, Issue 4, 1999, Pages 494-496

  Veyrac, G ^a   Chiffoleau, A ^a  

^a INSTITUT DE BIOLOGIE   (France)

Author keywords

Latanoprost; Systemic respiratory side effect

Indexed keywords

ANTIHYPERTENSIVE AGENT; EYE DROPS; LATANOPROST; PROSTAGLANDIN F; THROMBOXANE RECEPTOR;

AGED; ASTHMA; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG HYPERSENSITIVITY; HUMAN; LETTER; MALE; OPEN ANGLE GLAUCOMA; PHYSIOLOGY; RESPIRATORY TRACT ALLERGY;

AGED; ANTIHYPERTENSIVE AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL SPASM; DRUG HYPERSENSITIVITY; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, THROMBOXANE; RESPIRATORY HYPERSENSITIVITY;

EID: 0033154385     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996; 9: 363-378.
2. Begaud B, Evreux JC, Jouglard J et al .Imputabilité des effets inattendus toxiques des médicaments. Thérapie 1985; 40: 111-118.
3. Kabi Pharmacia. Report L411 C037: Effects of intravenous administration of PHxA41 on airway resistance and regional blood flow in vital organs of the cynomolgus monkey.
4. Hutas I, Hadhazy P, Debreczeni L et al Relaxation of human isolated bronchial smooth muscle. Role of prostacyclin and prostaglandin F2a in muscle tone. Lung 1981; 159: 153-161.
5. Sweatman WJF, Collier HOJ. Effects of prostaglandins on human bronchial muscle. Nature 1968; 129: 1233-1238.
6. Mathé AA, Heqvist P. Effects of prostaglandins F2o< and E2 on airway conductance in healthy subjects and asthmatic patients. Am Rev RespirDis 1975; 111: 313-320.
7. Smith AP, Cuthbert MF, Dunlop LS. Effects of inhaled prostaglandins E], Eg and £3 on the airway resistance of healthy and asthmatic man. Clin Sci Mol Med 1975; 48: 421-430.
8. Mathé AA, Hedqvist P, Holmgren A et al Bronchial hyperreactivity to prostaglandin Fa and histamine in patients with asthma. AM/1973; 1: 193-196.
9. Featherstone RL, Robinson C, Holgate ST et al .Evidence for thromboxane receptor mediated contraction of guinea-pig and human airways in vitro by prostaglandin (PG) D2, 9 alpha, 11 beta-PGF2 and PGF2 alpha. Naunyn Schmiedebergs Arch Pharmacol 1990; 341: 439 - 443.
10. Stjernschantz J, Selen G, Sjöquist B et al .Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2a analogue. In: Samuelsson B et al , eds. Advances in Prostaglandin, Tromboxane and Leukotrime Research, Vol. 23. New York: Raven Press, 1995: 513-518.
11. Hedner J, Svedmyr N, Lunde H, et al .The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Suru Ophtalmol 1997; 41 (suppl 2): S111-S115.
12. Martindale - The Extra Pharmacopoeia, 31st edn. London: Pharmaceutical Press, 1996. [Dinoprost et Latanoprost: 1453-1454 et 1459.]
13. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998; 105: 82-87.
14. Aim A. Prostaglandin dérivâtes as ocular hypotensive agents. Prog Retin Eye Res 1998; 17: 291-312.